5-HT<sub>2A</sub> receptors in layer 5 pyramidal neurons mediate the neuroplastic but not the hallucinogenic effects of psilocybin. [PDF]
Baker JJ, Kogan E, Ma S, Lu J, Zuo Y.
europepmc +1 more source
Changes in self-related cognitive processes and depressive symptom severity following a single, moderate dose of psilocybin in depressed patients. [PDF]
Belinger L +11 more
europepmc +1 more source
Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis. [PDF]
Florineth GA +7 more
europepmc +1 more source
Direct Quantitation of Psilocybin and Psilocin by <sup>1</sup>H and <sup>31</sup>P qNMR in Wild <i>Psilocybe</i> from Greece. [PDF]
Dadiotis E +10 more
europepmc +1 more source
Apomorphine and psilocybin to improve recovery from coma in the intensive care unit: protocol for a prospective, open-label, dose-escalation study. [PDF]
Eigenbrodt AK +7 more
europepmc +1 more source
Preparing the body for psilocybin therapy: receptive and generative interoception in cancer patients. [PDF]
Back AL +3 more
europepmc +1 more source
Matters arising: Methodological concerns and interpretative limitations of assessing subjective effects of ketamine. [PDF]
Janavičius R.
europepmc +1 more source
Prior trauma shapes the effects of psilocybin on stress sensitization in mice. [PDF]
Ottofaro SR +2 more
europepmc +1 more source
Psychedelic assisted psychotherapy (2020-2025): a scoping review of clinical evidence, mechanisms, safety, and ethics. [PDF]
Abdullahi NM +9 more
europepmc +1 more source
A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults. [PDF]
Levy-Cooperman N +7 more
europepmc +1 more source

